[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuroendocrine-carcinomas\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuroendocrine-carcinomas":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,52,76,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100606363","phase-1-a-study-of-ide849-in-patients-with-dll3-expressing-tumors-including-small-cell-lung-cancer-100606363",false,"NCT07174583","A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer","A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients With DLL3-Expressing Tumors Including Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Are willing to participate in this clinical study, understand the study procedures, and are able to sign the written ICF.\n2. Subjects with histologically or cytologically confirmed ES- SCLC, neuroendocrine carcinoma (NEC), DLL3+ solid tumors, are eligible per protocol. Subjects must have radiologically progressed or recurred after previous standard treatment.\n\n   For SCLC, this includes platinum-based therapy and programmed death-1\u002Fprogrammed death-ligand 1 inhibitors (except for subjects who refuse, or are judged by the Investigator to be unsuitable, or were intolerant to immunotherapy and chemotherapy may enroll to receive monotherapy or IDE161 combination.\n3. Subjects with NEC, this includes\n\n   * High-grade gastroenteropancreatic NEC\n   * NEC of the prostate\n   * Small cell NEC of any other organ\n   * Merkel cell carcinoma\n   * Transformed non-small cell adenocarcinoma of the lung (including but not limited to epidermal growth factor receptor or Kirsten rat sarcoma viral oncogene homolog mutated adenocarcinoma of the lung post progression on targeted therapies\n   * Any other NEC that does not meet any of the indications noted above.\n4. Subjects with other solid tumors demonstrated to express moderate\u002Fhigh expression of DLL3 including metastatic melanoma, Grade 3 gastrointestinal and pancreatic NETs, and pulmonary carcinoids.\n\n   • metastatic melanoma\n5. Subjects will be required to provide blood\u002Ftumor tissue samples for biomarker testing.\n6. Have at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n7. Have Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.\n8. Have life expectancy \\> 3 months.\n9. Have adequate bone marrow and organ function within 7 days of the first dose (no use of any blood components and\u002For cell growth factors within 14 days prior to the start of the study treatment).\n10. Women of childbearing potential (WOCBP) must agree to take highly effective contraceptive measures from signing of consent through 8 months after the last dose of IDE849; men with partners of child-bearing potential must use effective contraception through 5 months after the last dose.\n\nExclusion Criteria:\n\n1. Have mixed SCLC and NSCLC histology are not allowed (SCLC with components of large cell NEC are eligible). Participants with limited stage SCLC are ineligible.\n2. Subjects with locally untreated (radiotherapy or surgery) or active central nervous system (CNS) tumor metastasis.\n3. Have had other malignancies within 2 years prior to the first dose, except adequately treated carcinoma in situ (cervical, breast, or other), basal cell or squamous cell skin cancer, localized prostate cancer after curative therapy with no recurrence, or papillary thyroid cancer after curative resection; other prior or concurrent malignancies may be eligible with Medical Monitor review and approval.\n4. Have uncontrolled tumor-associated pain.\n5. Have severe cardiovascular and cerebrovascular disease\n6. Have history of clinically significant bleeding within 3 months before the first study dose.\n7. Have history of interstitial pneumonitis during previous treatment; current noninfectious pneumonitis requiring steroid therapy; known or suspected interstitial pneumonitis as seen on screening imaging; other moderate to severe lung diseases seriously affecting respiratory function within 3 months before the first dose, including, but not limited to, idiopathic pulmonary fibrosis and organizing pneumonia\u002Fobliterative bronchiolitis.\n8. Have history of immunodeficiency, with a positive human immunodeficiency virus (HIV) test at screening (HIV antibody positive and HIV-RNA above the lower limit of detection of the analytical method).\n9. Subjects with known or suspected viral hepatitis.\n10. Have a history of active tuberculosis within 1 year before enrollment.\n11. For participants enrolling to receive the combination with durvalumab, must not be deemed by the Investigator to be unsuitable to receive immunotherapy, or have had any prior intolerance to PD-1\u002FPD-L1 inhibitor therapy, or have had any prior Grade 2 or higher myocarditis or any other Grade 3 or higher immune-related AE. If the participant has had a prior immune-related AE, must have recovered to Grade \\\u003C 1.\n12. For participants enrolling to receive the combination with IDE161, must not have had prior GI or upper bowel removal or any other gastrointestinal disorder or defect (eg, malabsorption disorder such as Crohn's disease or ulcerative colitis), that would interfere with absorption of IDE161.\n13. For patients receiving a combination with carboplatin, be deemed by the Investigator to be unsuitable to receive platinum-based chemotherapy, or have had intolerance to platinum-based chemotherapy\n14. Have received chemotherapy within 3 weeks of first dose of IMP; immunotherapy or biologic targeted antitumor treatments within 2 weeks before the first dose of IMP; for small molecule treatments within 2 weeks before the first dose of the IMP or within 5 half lives of the drug (whichever is longer); other investigational products within 4 weeks or within 5 half-lives of the drug (whichever is longer) unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study. Participants who received an immunotherapy agent (eg, PD-1\u002FPD-L1 inhibitor) immediately prior to study enrollment must have documented radiologic disease progression as per the Investigator prior to the first dose of IMP\n15. Administration of any of the following:\n\n    * Use of drugs that are inhibitors of P-gp, BCRP, and OATPIB1\u002FOATP1B3\n    * Use of drugs with known risk of QT prolongation within 5 half-lives of their administration.\n16. For participants enrolling to receive the combination with IDE161:\n\n    * Use of drugs of narrow therapeutic index that are sensitive substrates of MATE2-K, BCRP, and P-gp\n    * Use of known moderate and strong CYP3A4\u002F5 inducers and inhibitors is not permitted\n    * Administration of PPIs\n    * Use of an H2 blocking agent\n    * Use of a local antacid\n    * Use of drugs with a known risk of QT prolongation\n17. Have prior treatment with DLL3 ADC with a Topo1 inhibitor payload (except for participants enrolling to receive the IDE161 combination).\n18. For participants enrolling to receive the combination with durvalumab, have history of prior intolerance to PD-1\u002FPD-L1 inhibitors.\n19. Have received \\> 30 Gy of chest radiotherapy within 8 weeks prior to the first dose of the IMP, \\> 30 Gy of non-chest radiotherapy within 14 days prior to the first dose (subjects who have completed radiotherapy for brain metastases within 14 days prior to the first dose can be enrolled and palliative radiotherapy for other sites of ≤ 30 Gy is allowed if completed more than 14 days prior to the first dose).\n20. Have undergone major surgery or experienced significant trauma within 4 weeks prior to the first dose.\n21. Female subjects who are pregnant, lactating, or planning to become pregnant during the study period to 8 months after the last dose of the IMP.","ALL","18 Years",{"count":19,"type":20},262,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This is Phase 1\u002F2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.",[27,28,29],"Small-cell Lung Cancer","Neuroendocrine Carcinomas","Solid Tumor Show to Express DLL3",[31,32,33,34,35,28,36,37,38],"IDE849","Small Cell Lung Cancer","SCLC","anti-DLL3 immunoglobulin G1 monoclonal antibody","DLL3","NEC","durvalumab","IDE161","RECRUITING","2026-07-07",{"date":42,"type":43},"2026-07-09","ACTUAL",{"date":45,"type":43},"2025-10-14",{"date":47,"type":20},"2029-07",{"name":49,"class":50},"IDEAYA Biosciences","INDUSTRY",13,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100647050","phase-2-study-of-ctx-471-in-patients-with-neural-cell-adhesion-molecule-ncam-positive-neuroendocrine-neoplasms-100647050","NCT07684170","Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms","A Phase 2, Open-Label Study of CTX-471 in Patients With NCAM Positive Tumors","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Positive immunohistochemical staining for NCAM (defined as ≥ 1% of malignant cells with membranous\u002Fcytoplasmic staining of any intensity) on an archived (≤ 3 months) or freshly taken biopsy specimen (centrally tested) with histologically confirmed diagnosis of metastatic tumors.\n3. Locally advanced unresectable or metastatic neuroendocrine neoplasm (NEN) defined by World Health Organization (WHO) (Rindi et al 2022) Grade 3 neuroendocrine tumor (NET) or neuroendocrine carcinoma (NEC) (Ki-67 \\> 20% and\u002For \\> 20 mitoses\u002F10 hpf) and confirmed by histopathology or cytology (eg, gastroentero-pancreatic NECs (GEP-NEC) and lung NEC, other rare sites of origin such as genitourinary, gynecological, larynx, thyroid, or unknown origin).\n4. Patients must have received at least one prior line of chemotherapy and must have exhausted any other standard-of-care treatment option.\n\n   a. Patients with histologically confirmed prostate NEC are not required to have received prior androgen deprivation therapy (ADT) or castrated levels of testosterone.\n5. A washout period of 4 weeks or at least 5-fold half-life of the last dose (whichever is shorter) of prior systemic therapy prior to receiving the first dose of CTX-471.\n\n   • The eligibility of patients who received unapproved drugs will be determined by discussion with the Sponsor Medical Monitor.\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n7. At least one measurable lesion definable by MRI or CT scan per RECIST version 1.1 criteria.\n8. All toxicities related to previous anti-cancer therapies have resolved to (CTCAE) Grade 1 prior to trial treatment administration (except for alopecia, peripheral neuropathy, fatigue and endocrinopathies controlled by replacement therapy which must be CTCAE Grade 2 and amenorrhea\u002Fmenstrual disorders which can be any grade).\n9. Adequate organ function and laboratory values:\n\n   * Adequate bone marrow function defined by absolute neutrophil (ANC) of ≥ 1.5×109\u002FL, platelet count of ≥ 100.0×109\u002FL, and hemoglobin of ≥ 9.0 g\u002FdL (with or without transfusion).\n   * Adequate hepatic function defined as serum total bilirubin ≤ 1.5 × ULN, AST\u002FALT ≤ 2.5 × ULN (or ≤ 5 × ULN in patients with liver metastases or ≤3 x ULN for patients with Gilbert's syndrome).\n   * Adequate renal function defined as creatinine clearance ≥ 30 mL\u002Fmin by Cockcroft-Gault equation.\n10. Females of childbearing potential (FOCBP) should have a negative serum pregnancy within 72 hours prior to receiving the first dose of study medication.\n11. FOCBP must agree to use adequate contraception as outlined in study documentation, starting with the first dose of study medication through 120 days after the last dose of study medication.\n12. Male patients of childbearing potential must agree to use an adequate method of contraception as outlined in study documentation, starting with the first dose of study medication through 120 days after the last dose of study medication.\n13. Capable of understanding and complying with protocol requirements.\n14. Signed and dated institutional review board (IRB) approved informed consent form (ICF) before any protocol-directed screening procedures are performed.\n\nExclusion Criteria:\n\n1. Diagnosis of well differentiated G1\u002FG2 neuroendocrine neoplasm.\n2. Prior history of interstitial lung disease.\n3. Prior treatment of CD137 targeted therapy (investigational and approved).\n4. Symptomatic or uncontrolled central nervous system and brain metastasis or active leptomeningeal disease. Patients with equivocal findings or with confirmed brain metastases are eligible for the study provided that they are asymptomatic and radiologically and neurologically stable without the need for corticosteroid treatment or seizure prophylaxis for ≥4 weeks before the first dose of study drug. Prior treatment with either surgery or radiation is permitted and all patients with a history of central nervous system (CNS) or brain lesions require imaging during screening to confirm stability.\n5. Prior solid organ transplantation and\u002F or an allogeneic tissue transplant.\n6. Active hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection or a positive serological test at Screening within 35 days of dosing with CTX-471.\n\n   * Hepatitis B surface antigen (HBsAg) positive patients are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization.\n   * HBV+ patients should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention.\n   * History of HCV infection is eligible if HCV viral load is undetectable at screening.\n   * HCV+ patients must have completed curative anti-viral therapy at least 4 weeks prior to randomization.\n7. HIV-infected patients must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection\u002Fdisease defined as:\n\n   * Patients on ART must have a CD4+ T-cell count \\\u003C 350 cells\u002Fmm3 at time of screening.\n   * Patients on ART must have achieved and maintained virologic suppression defined as confirmed HIV RNA level below 50 copies\u002FmL or the lower limit of qualification (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks prior to screening.\n   * Patients on ART must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks prior to study entry (Day 1).\n8. Active autoimmune disease or medical conditions requiring chronic steroid (ie, \\> 10 mg\u002Fday prednisone or equivalent) or immunosuppressive therapy. Patients with a prior history of autoimmune disease may be eligible following discussion with the Medical Monitor.\n9. Systemic therapy with immunosuppressive agents within 7 days before the start of CTX-471 treatment. Topical, intranasal, intraocular, or inhaled corticosteroids and physiologic replacement for patients with adrenal insufficiency are allowed (≤ 10 mg\u002Fday prednisone or equivalent).\n10. Congestive heart failure (\\> New York Heart Association Class II), active coronary artery disease, unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or clinically significant cardiac arrhythmias.\n11. Other systemic conditions or organ abnormalities that in the opinion of the Investigator may interfere with the conduct and\u002For interpretation of the current study.\n12. Has received prior radiotherapy within 2 weeks of start of study treatment.\n\n    • Patients must have recovered from all radiation-related toxicities and not require corticosteroids.\n13. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study medication.\n\n    • Administration of killed vaccines are allowed.\n14. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n\n    * Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of bladder, that have undergone potentially curative therapy are not excluded.",{"count":60,"type":20},58,[24],"This study will enroll patients with central lab confirmed NCAM (CD56 IHC) positive metastatic neuroendocrine neoplasms that have progressed after standard of care treatment. CTX-471 to be administered as an intravenous (IV) infusion at either 0.3 mg\u002Fkg or 0.6 mg\u002Fkg every 2 weeks until disease progression or unacceptable toxicity. The study will be conducted in two stages. In Stage 1, 18 patients will be accrued for each dose level. If there are less than 2 objective responses in these 18 patients at either dose level, the dose level will be stopped. Otherwise, an additional 22 patients will be accrued in Stage 2 with 11 patients for each dose level.",[64,28,65],"Neuroendocrine Neoplasm","Neuroendocrine Tumors","NOT_YET_RECRUITING","2026-07-01",{"date":69,"type":43},"2026-07-06",{"date":71,"type":20},"2026-09",{"date":73,"type":20},"2029-09",{"name":75,"class":50},"Compass Therapeutics",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":109},"100519282","phase-1-a-first-in-human-phase-i-trial-with-antibody-drug-conjugate-adct-701-in-neuroendocrine-tumors-carcinomas-and-malignant-peripheral-nerve-sheath-tumors-100519282","NCT06041516","A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors","* INCLUSION CRITERIA:\n* Participants must have histologically or cytologically confirmed neuroendocrine neoplasms or malignant adrenocortical carcinoma (ACC) or malignant peripheral nerve sheath tumors (MPNST).\n* Locally advanced, unresectable or metastatic disease (as confirmed by a radiological evaluation)\n* Participants must have measurable disease per RECIST 1.1.\n* Participants must have received prior standard of care treatment and be refractory to or intolerant to standard of care therapy(s). Note: Patients with MPNST who have refused cytotoxic chemotherapy or for whom treatment on this protocol prior to receiving cytotoxic\n\nchemotherapy is felt to be in the best interest for the patient by the local investigator and treating investigator will also be eligible.\n\n* Age \\>= 18 years.\n* ECOG performance status \\\u003C= 2.\n* Adequate hematologic function as follows:\n\n  * Leukocytes \\>= 3,000\u002Fmicroliter\n  * Absolute neutrophil count (ANC) \\>= 1,200\u002Fmicroliter (off-growth factors for 72 hours prior to treatment initiation)\n  * Hemoglobin (Hgb) \\>= 9 g\u002FdL with no blood transfusion within 2 weeks prior to treatment initiation\n  * Platelets \\>= 100,000\u002Fmicroliter with no platelet transfusion within 1 week.\n* Adequate renal and hepatic function as follows:\n\n  * Creatinine clearance (CrCl) \\>= 50 mL\u002Fmin\u002F1.73 m\\^2 (calculated CrCl (Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) or calculated eGFR provided by a laboratory))\n  * Total bilirubin \\\u003C= 1.5 x ULN OR in participants with known or suspected Gilbert's syndrome, total bilirubin \\\u003C= 3.0 x ULN\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\\u003C= 2.5 x ULN, (unless liver metastases are present, then values must be \\\u003C= 5 x ULN).\n* Participants serologically positive for hepatitis C virus (HCV) must have an undetectable HCV viral load.\n* Participants serologically positive for Hepatitis B (HBV) core antibody or surface antigen must be on adequate anti-viral therapy and Hepatitis B Viral deoxyribonucleic acid (DNA) load must be \\\u003C2000 IU\u002FmL.\n* Participants serologically positive for human immunodeficiency virus (HIV) must be on stable antiretroviral therapy for at least 4 weeks before treatment initiation, have no reported opportunistic infections or Castleman s disease within 12 months prior to treatment initiation, have a viral load that is undetectable by quantitative polymerase chain reaction (PCR) and CD4 count \\>= 200 cells per cubic millimeter.\n* Participants with brain metastasis are eligible if at least 4 weeks status post radiotherapy or surgery before treatment initiation with no evidence of progression or associated symptoms.\n* Individuals of child-bearing potential (IOCBP) must agree to use a highly effective method of contraception (hormonal, intrauterine device (IUD), surgical sterilization) for the duration of the study treatment and up to 9.5 months after the last dose of the ADCT-701 (restriction period).\n\nIndividuals who can father children must agree to use an effective method of contraception (barrier, surgical sterilization) at study entry and up to 6.5 months after the last dose of the ADCT-701.\n\n* Nursing participants must be willing to discontinue nursing from study treatment initiation through 6.5 months after study treatment discontinuation.\n* Participants or legally authorized representative (LAR) must be able to understand and be willing to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* Major surgery, prior treatment with chemotherapy, hormonal therapy, immunotherapy, treatment with an investigational agent, and\u002For radiation therapy within 4 weeks or 5 half-lives, whichever is shorter, prior to treatment initiation.\n* Participants taking any herbal supplements within 14 days prior to treatment initiation.\n* Participants who have wound dehiscence from prior surgeries.\n* Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or any serosal effusion that is either requires drainage or is associated with shortness of breath) at screening.\n* Active infection requiring systemic antibiotic therapy at screening.\n* Active bleeding diathesis or therapeutic anticoagulation with an oral vitamin K antagonist with target international normalized ratio (INR) \\> 2 at screening.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drug.\n* An active autoimmune disease. Note: Participants with type 1 diabetes, eczema, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease, adrenal insufficiency on systemic oral corticosteroid therapy (\\\u003C= the equivalent of prednisone 10 mg\u002Fday), or other mild autoimmune disorders (Type 1 diabetes, eczema, vitiligo, alopecia, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, adrenal insufficiency due to Addison's disease, hypothyroidisms due to Hashimoto's thyroiditis, hyperthyroidisms due to Graves disease, Sjogren s syndrome, celiac disease, pernicious anemia) not requiring immunosuppressive treatment are eligible.\n* Congenital long QT syndrome, or a corrected QTcF interval of \\>=480 ms, at screening (unless secondary to the pacemaker or bundle branch block).\n* Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that does not require current anticancer treatment per standard of care.\n* Live vaccine administration within 30 days prior to treatment initiation.\n* Pregnant individuals (confirmed by Beta-Human Chorionic Gonadotropin \\[Beta-HCG\\] serum or urine pregnancy test) performed at screening.\n* Uncontrolled intercurrent illness that would limit compliance with study requirements.","120 Years",{"count":84,"type":20},70,[23],"Background:\n\nNeuroendocrine neoplasms (NENs) are rare cancers in the gastrointestinal tract, pancreas, lungs, adrenal glands, and other areas of the body. Many of these cancers have a high risk of relapse and a low chance of survival. Better treatments are needed.\n\nObjective:\n\nTo test a new drug, ADCT-701, in people with NENs.\n\nEligibility:\n\nAdults aged 18 and older with NENs.\n\nDesign:\n\nParticipants will be screened. They will have a physical exam with blood and urine tests. They will have imaging scans and tests of heart functioning. Their ability to perform normal daily activities will be tested. A biopsy may be needed: A sample of tissue will be removed from the tumor.\n\nADCT-701 is given through a tube attached to a needle inserted into a vein in the arm. Participants will receive the drug treatment on the first day of 21-day treatment cycles. They will visit the clinic a total of 10 times during the first two cycles. After that, they will visit the clinic 2 times during each cycle. Imaging scans, blood draws, heart function tests, and other tests will be repeated during study visits. Each visit will last up to 8 hours.\n\nParticipants may continue receiving treatment with the study drug for up to 2 years.\n\nAfter treatment ends, participants will have follow-up clinic visits 4 times in 4 months. They will have a physical exam, with heart and blood tests, at each visit. After that, they will have follow-up clinic visits every 9 weeks; these visits will include imaging scans.\n\nFollow-up visits will continue for up to 5 years after treatment began....",[28,65,88,89,90],"Carcinoma, Neuroendocrine","Carcinoma, Adrenocortical","Carcinoma, Adrenal Cortical",[92,93,94,95,96,97,98],"Pheochromocytoma","Neuroblastoma","Neuroendocrine Tumor","Neuroendocrine carcinoma","Neuroendocrine neoplasms","Paraganglioma","Adrenocortical Carcinoma","2026-06-12",{"date":101,"type":43},"2026-06-15",{"date":103,"type":43},"2024-06-17",{"date":105,"type":20},"2029-10-30",{"name":107,"class":108},"National Cancer Institute (NCI)","NIH",1,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":4},"100607779","neuroendocrine-carcinomas-patient-journey-and-treatment-outcomes-in-latin-america-100607779","NCT07192991","Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America","NECTARINE","Inclusion Criteria:\n\n* ≥18 years old\n* Diagnosed between August 2014 and August 2024 with one of the following:\n* Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)\n* Large-cell neuroendocrine carcinoma (LCNEC) or mixed\n* Small Cell Lung Cancer (SCLC) or mixed\n* Adequate and accessible medical records for data collection\n* Tumor block collected from 2014 onwards\n\nExclusion Criteria:\n\n* Patients with active, concurrent malignancies at the time of NEC diagnosis, except for non-invasive cancers like basal cell carcinoma or squamous cell carcinoma of the skin, or in situ cervical cancer.\n* Patients or their legal representatives unwilling or unable to provide informed consent (if needed per ethics committee).",{"count":118,"type":20},200,"OBSERVATIONAL","This observational, retrospective study aims to understand the treatment patterns and outcomes of patients with pulmonary and extra-pulmonary neuroendocrine carcinomas (NEC) in Latin America (Brazil, Mexico, Argentina, and Peru). The research will collect data from medical records to analyze factors like patient demographics, diagnosis methods, tumor characteristics, treatment approaches, and disease progression. The study is non-interventional, meaning patient care will follow standard clinical practice, with data gathered via an electronic system.",[28,122],"Lung Neuroendocrine Carcinoma","2025-09-24",{"date":125,"type":43},"2025-09-25",{"date":127,"type":20},"2025-11-03",{"date":129,"type":20},"2026-09-30",{"name":131,"class":132},"Latin American Cooperative Oncology Group","OTHER"]